1. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices 
Esprit Ma, Vijayveer Bonthapally, Anita Chawla, Patrick Lefebvre, Ronan Swords, Marie-Hélène Lafeuille, Jonathan Fortier, Bruno Emond, Mei Sheng Duh, Bruce J. Dezube 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 16, Issue 11, Pages e3 (November 2016)
DOI: /j.clml
Copyright © 2016 The Author(s) Terms and Conditions

2. Figure 1
Disposition of Elderly Patient With AML. Altos Solutions (November 2005-February 2014). aTreatment Included Arsenic Trioxide, Azacitidine, Bortezomib, Cyclophosphamide, Cytarabine, Decitabine, Dexamethasone, Daunorubicin, Docetaxel, Doxorubicin, Epirubicin, Idarubicin, Methotrexate, Mitoxantrone, Rituximab, and Tretinoin. bCategory per Earlier NCCN Guidelines Recommendations.36 cSeven Days Cytarabine mg/m2 With 7 Days Idarubicin 12 mg/m2, or 3 Days Daunorubicin mg/m2, or 3 Days Mitoxantrone 12 mg/m2
Abbreviations: AML = acute myeloid leukemia; HU = hydroxyurea; NCCN = National Comprehensive Cancer Network.
Clinical Lymphoma, Myeloma and Leukemia  , e3DOI: ( /j.clml )
Copyright © 2016 The Author(s) Terms and Conditions

3. Figure 2
Overall Survival From (A) AML Diagnosis, (B) First AML Treatment
Abbreviations: AML = acute myeloid leukemia; BSC = best supportive care; HU = hydroxyurea; NR = not reached.
Clinical Lymphoma, Myeloma and Leukemia  , e3DOI: ( /j.clml )
Copyright © 2016 The Author(s) Terms and Conditions